Adding daratumumab (Darzalex) to standard treatment helped certain people with multiple myeloma live longer without their cancer getting worse or dying. People taking daratumumab were also more likely to have no detectable signs of cancer after treatment.
Under a new Food and Drug Administration (FDA) approval, enzalutamide (Xtandi) can now be used alone or with leuprolide to treat some people with nonmetastatic prostate cancer. FDA’s decision was based on the results of a large clinical trial called EMBARK.
FDA approved toripalimab (Loqtorzi) based on the results of a large clinical trial. The trial showed that, when added to chemotherapy, the drug helped certain people with nasopharyngeal cancer live longer.
In a clinical trial, a letter and phone call helped increase the number of people who completed the recommended follow-up testing after an abnormal result from a cancer screening test.
Vivian, a proud member of the Navajo Nation, is also a clinical trial participant. "Cancer doesn’t have to be a death sentence. I’m a testament to that," Vivian said.
Clinical Trials Information for Patients and Caregivers
Participating in a cancer screening trial can help find new ways to detect cancer early when it may be more easily treated. Learn more about what cancer screening clinical trials are and what may be involved if you join one.
In this video, researchers in the NCI Community Oncology Research Program (NCORP) describe this national network and talk about how it brings clinical trials to diverse populations in their own communities.
This phase 2 ComboMATCH trial is testing a combination of FDA-approved drugs, binimetinib (Mektovi) and palbociclib (Ibrance), for people with cancers that test positive for mutations in a group of genes called RAS. People with RAS-mutated low-grade ovarian cancer, pancreatic, or other cancers will be assigned randomly to either combination therapy with binimetinib and palbociclib or treatment with binimetinib alone.
This phase 2 trial will test the addition of the drug olaparib (Lynparza) to standard chemotherapy for people with advanced neuroendocrine cancers. Olaparib helps prevent DNA in cancer cells from repairing itself, leading to cancer cell death. Doctors want to see if giving olaparib together with chemotherapy helps people live longer without their cancer growing.
This phase 2 trial will test the effectiveness of combining nivolumab (Opdivo) and cabozantinib (Cabometyx) to treat people with melanoma or squamous cell head and neck cancer that has spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors.
